Moreover, early‐phase clinical studies support this hypothesis: the TOPACIO/KEYNOTE‐162 trial of niraparib plus pembrolizumab reported an ORR of ~21% with durable responses in some BRCA1/2‐mutated patients, the MEDIOLA study of olaparib plus durvalumab showed high disease control in BRCA‐mutated breast cancer, and the JAVELIN BRCA/ATM trial of avelumab plus talazoparib demonstrated antitumor activity in BRCA1/2‐ or ATM‐altered tumors [26, 27, 28]. Here, ATM is linked to breast carcinoma.